IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
This study has been completed.
Sponsor:
Keryx Biopharmaceuticals
Collaborator:
Collaborative Study Group (CSG)
Information provided by (Responsible Party):
Keryx Biopharmaceuticals
ClinicalTrials.gov Identifier:
NCT00648167
First received: March 27, 2008
Last updated: March 3, 2017
Last verified: March 2017
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study is to evaluates the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease.
| Condition | Intervention | Phase |
|---|---|---|
| Hyperphosphatemia End-stage Renal Disease | Drug: ferric citrate | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: No masking Primary Purpose: Treatment |
| Official Title: | A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) |
Resource links provided by NLM:
Further study details as provided by Keryx Biopharmaceuticals:
Primary Outcome Measures:
- The Difference in Serum Phosphorus Between Baseline (Day 0) and End of Treatment (Day 28) [ Time Frame: 28 days ]
| Enrollment: | 55 |
| Study Start Date: | March 2008 |
| Study Completion Date: | January 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: KRX-0502 (ferric citrate)
All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
|
Drug: ferric citrate
ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
Other Name: KRX-0502
|
Detailed Description:
The purpose of this study is to evaluate the safety and tolerability of Zerenex™ (ferric citrate) as a treatment for hyperphosphatemia in patients with End-Stage Renal Disease. These patients will be switched to Zerenex™ from their current high dose of phosphate binder and, based on their serum phosphorus levels, will be titrated up from 3.4g/day of Zerenex™ to maximum tolerated and safe doses of Zerenex™. Doses will be adjusted weekly, based on serum phosphorus levels, with the maximum dose administered being approximately 12g/day.
Eligibility| Ages Eligible for Study: | 19 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males and non-pregnant, nonlactating females
- Age > 18 years
- On thrice weekly hemodialysis for at least the previous 3 months prior to randomization
- Phosphorous levels ≥3.5mg/dL at Screening Visit
- On at least 12 tablets/capsules/day of calcium acetate (667mg), calcium carbonate (500mg), lanthanum carbonate (500mg), sevelamer hydrochloride (800mg or two 400mg tablets), or any combination of these agents
- Serum ferritin <1000micrograms/L and Transferrin Saturation (TSAT) <50%
- Willing to be discontinued from current phosphate binder(s) and initiated on Zerenex
- Willing and able to give informed consent
Exclusion Criteria:
- Parathyroidectomy within 6 months prior to Screening
- Actively symptomatic GI disease such as peptic ulcer disease, gastro esophageal reflux, diverticulosis, irritable bowel syndrome (treated asymptomatic is permitted)
- History of documented inflammatory bowel disease or erosive esophagitis
- Serum Phosphorus levels >10.0 mg/dL documented in the 3 monthly laboratories (done routinely in the dialysis unit) in the 3 months prior to the Screening Visit
- History of multiple drug allergies
- History of malignancy in the last 5 years (treated cervical or skin cancer may be permitted if approved by CCC)
- Previous intolerance to oral ferric citrate
- Absolute requirement for oral iron therapy
- Absolute requirement for Vitamin C (multivitamins [Neprocaps, Renaphro, etc.] allowed)
- Absolute requirement for calcium, magnesium, or aluminum containing drugs with meals
- Psychiatric disorder that interferes with the patient's ability to comply with the study protocol
- Inability to tolerate oral drug intake
- Planned surgery or hospitalization during the study (scheduled outpatient access surgery allowed)
- Any other medical condition that renders the patient unable to or unlikely to complete the study or that would interfere with optimal participation in the study or produce significant risk to the patient
- Receipt of any investigational drug within 30 days of randomization
- Inability to cooperate with study personnel or history of noncompliance
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00648167
Please refer to this study by its ClinicalTrials.gov identifier: NCT00648167
Locations
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
Sponsors and Collaborators
Keryx Biopharmaceuticals
Collaborative Study Group (CSG)
Investigators
| Study Chair: | Julia B Lewis, MD | Collaborative Study Group at the Nephrology Clinical Trials Center, Vanderbilt University Medical Center |
More Information
Additional Information:
| Responsible Party: | Keryx Biopharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00648167 History of Changes |
| Other Study ID Numbers: |
KRX-0502-201 |
| Study First Received: | March 27, 2008 |
| Results First Received: | October 4, 2014 |
| Last Updated: | March 3, 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Keywords provided by Keryx Biopharmaceuticals:
|
ESRD end-stage renal disease end stage renal disease hemodialysis dialysis kidney failure |
renal failure kidney renal phosphate binder phosphorus |
Additional relevant MeSH terms:
|
Kidney Diseases Kidney Failure, Chronic Renal Insufficiency, Chronic Hyperphosphatemia Urologic Diseases Renal Insufficiency Phosphorus Metabolism Disorders Metabolic Diseases |
Citric Acid Ferric Compounds Anticoagulants Calcium Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action Hematinics |
ClinicalTrials.gov processed this record on July 21, 2017